Table 2.
Safety Profile of Cediranib (30-mg daily) in advanced HCC patients
| Toxicity (N=17) | Grade 1–4 (%) | Grade 3 (%) | Grade 4 (%) |
|---|---|---|---|
| Fatigue | 14 (82) | 1 (6) | - |
| AST-SGOT | 12 (71) | 2 (12) | - |
| Hyponatremia | 11 (65) | 5 (29) | - |
| Diarrhea | 10 (59) | - | - |
| Nausea | 9 (53) | - | - |
| Alk.Phosphatemia | 8 (47) | 1 (6) | - |
| ALT-SGPT | 8 (47) | 1 (6) | - |
| Weight loss | 8 (47) | - | - |
| Anorexia | 7 (41) | - | - |
| hyperbilirubinemia | 7 (41) | 3 (18) | 1 (6) |
| Hypertension | 7 (41) | 5 (29) | - |
| Hypophosphatemia | 7 (41) | 1 (6) | - |
| Proteinuria | 7 (41) | 1 (6) | - |
| Thrombocytopenia | 6 (35) | - | - |
| Vomiting | 6 (35) | - | - |
| Dehydration | 5 (29) | 1 (6) | - |
| Hypocalcemia | 5 (29) | - | - |
| Leukopenia | 5 (29) | - | - |
| Lymphopenia | 5 (29) | 1 | - |
| Cough | 4 (24) | - | - |
| Anemia | 4 (24) | - | - |
| Hyperkalemia | 4 (24) | - | - |
| Rash/desquamation | 4 (24) | - | - |
| Fever w/o neutropenia | 3 (18) | - | - |
| Hypoglycemia | 3 (18) | - | - |
| Hypothyroidism | 3 (18) | 1 (6) | - |
| Confusion | 2 (12) | - | - |
| Creatinine | 2 (12) | - | - |
| Hand-foot skin reaction | 2 (12) | - | - |
| Hypokalemia | 2 (12) | - | - |
| Stomatitis | 2 (12) | - | - |
| Headache | 2 (12) | - | - |
| Taste disturbance | 2 (12) | - | - |
| Dysphonia | 2 (12) | - | - |
| Cardiac ischemia | 1 (6) | 1 (6) | - |
| Hematemesis | 1 (6) | 1 (6) | - |
| Hypercalcemia | 1 (6) | - | - |
| Epistaxis | 1 (6) | - | - |
| Pulmonary embolism | 1 (6) | - | 1 (6) |